{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:24:24Z","timestamp":1765725864159,"version":"3.48.0"},"reference-count":25,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/501100011447","name":"Henan Provincial Science and Technology Department","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,7,24]]},"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in\n                      <jats:italic>CD133<\/jats:italic>\n                      (\n                      <jats:italic>rs2240688<\/jats:italic>\n                      A&gt;C,\n                      <jats:italic>rs10022537<\/jats:italic>\n                      T&gt;A,\n                      <jats:italic>rs7686732<\/jats:italic>\n                      C&gt;G, and\n                      <jats:italic>rs3130<\/jats:italic>\n                      C&gt;T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Department of General Surgery, in a general hospital, Henan Province, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>NSCLC patients aged \u226518 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion. Those participants who were pregnant or breastfeeding, had a previous history of cancer, had other primary tumours, or who had had primary tumours of the skin and nasopharynx, were excluded from the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was a total of 1383 participants, with a median age of 63 years; 726 (52.5%) were male. Compared with the\n                      <jats:italic>rs2240688<\/jats:italic>\n                      AA genotype, the variant AC\/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95%\u2009CI 1.91 to 2.80 for CC genotype). Higher hazard ratios for associations between\n                      <jats:italic>CD133 rs2240688<\/jats:italic>\n                      polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95%\u2009CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95%\u2009CI 1.55 to 2.33).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The study confirmed the significant association between the SNP\n                      <jats:italic>rs2240688 A&gt;C<\/jats:italic>\n                      of CD133 and OS of NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms of\n                      <jats:italic>CD133<\/jats:italic>\n                      in NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-016913","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T20:10:25Z","timestamp":1503346225000},"page":"e016913","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Polymorphisms of the stem cell marker gene\n                    <i>CD133<\/i>\n                    are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients"],"prefix":"10.1136","volume":"7","author":[{"given":"Qing-Feng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Henan Provincial People\u2019s Hospital (Zhengzhou University People's Hospital), Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Fei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Henan Provincial People\u2019s Hospital (Zhengzhou University People's Hospital), Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Jie","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Henan Provincial People\u2019s Hospital (Zhengzhou University People's Hospital), Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Henan Provincial People\u2019s Hospital (Zhengzhou University People's Hospital), Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Henan Provincial People\u2019s Hospital (Zhengzhou University People's Hospital), Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"2025121407214040000_7.8.e016913.1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0437"},{"key":"2025121407214040000_7.8.e016913.2","first-page":"1","article-title":"Predicting diagnostic gene biomarkers for non-small-cell lung cancer","volume":"2016","author":"Liang","year":"2016","journal-title":"Biomed Res Int"},{"key":"2025121407214040000_7.8.e016913.3","doi-asserted-by":"crossref","first-page":"56526","DOI":"10.18632\/oncotarget.10964","article-title":"The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"2025121407214040000_7.8.e016913.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21149"},{"key":"2025121407214040000_7.8.e016913.5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.semtcvs.2014.09.001","article-title":"Current innovations in sentinel lymph node mapping for the staging and treatment of resectable lung cancer","volume":"26","author":"Hachey","year":"2014","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2025121407214040000_7.8.e016913.6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/etm.2011.368","article-title":"Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: a meta-analysis of randomized controlled trials","volume":"3","author":"Matsuda","year":"2012","journal-title":"Exp Ther Med"},{"key":"2025121407214040000_7.8.e016913.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2008.07.012"},{"key":"2025121407214040000_7.8.e016913.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-007-9002-0"},{"key":"2025121407214040000_7.8.e016913.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0097-1"},{"key":"2025121407214040000_7.8.e016913.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0530291100"},{"key":"2025121407214040000_7.8.e016913.11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2162-3619-2-17","article-title":"CD133: a stem cell biomarker and beyond","volume":"2","author":"Li","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"2025121407214040000_7.8.e016913.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.11.003"},{"key":"2025121407214040000_7.8.e016913.13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3892\/or_00000890","article-title":"Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma","volume":"24","author":"Sasaki","year":"2010","journal-title":"Oncol Rep"},{"key":"2025121407214040000_7.8.e016913.14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/mc.22113","article-title":"Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer","volume":"54","author":"Wang","year":"2015","journal-title":"Mol Carcinog"},{"key":"2025121407214040000_7.8.e016913.15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1703-6"},{"key":"2025121407214040000_7.8.e016913.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2010.05.006"},{"key":"2025121407214040000_7.8.e016913.17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3175"},{"key":"2025121407214040000_7.8.e016913.18","first-page":"32","article-title":"Prognostic value of CD133 expression in stage I lung adenocarcinomas","volume":"4","author":"Woo","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"key":"2025121407214040000_7.8.e016913.19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00408-016-9876-1","article-title":"Polymorphisms of the stem cell marker gene CD133 and the risk of lung cancer in Chinese population","volume":"194","author":"Liu","year":"2016","journal-title":"Lung"},{"key":"2025121407214040000_7.8.e016913.20","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt181"},{"key":"2025121407214040000_7.8.e016913.21","first-page":"5509","article-title":"Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer","volume":"8","author":"Su","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2025121407214040000_7.8.e016913.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095915","article-title":"Cancer stem cell marker Musashi-1 rs2522137 genotype is associated with an increased risk of lung cancer","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"2025121407214040000_7.8.e016913.23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0530"},{"key":"2025121407214040000_7.8.e016913.24","first-page":"981","article-title":"Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer","volume":"33","author":"Gottschling","year":"2013","journal-title":"Anticancer Res"},{"key":"2025121407214040000_7.8.e016913.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.02.006"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-016913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:21:52Z","timestamp":1765725712000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-016913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,21]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/bmjopen-2017-016913"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-016913","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}